ALLMedicine™ Hemophilia B Center
Research & Reviews 530 results
https://clinicaltrials.gov/ct2/show/NCT03358836
Jun 22nd, 2022 - This is a prospective, non-randomized, controlled study to examine whether or not having a higher trough during prophylactic treatment with clotting factor offers better joint protection than the standard trough of 1% Factor IX (FIX or Factor 9). ...
https://doi.org/10.1002/pbc.29811
Pediatric Blood & Cancer; Kracht MJ, Stein A et. al.
Jun 17th, 2022 - Hemophilia is the deficiency of plasma clotting factor VIII (hemophilia A) or IX (hemophilia B) where management focuses on the prevention and treatment of acute bleeding symptoms and their sequelae. The most concerning risk is for life-threatenin...
https://doi.org/10.1016/j.ymthe.2022.06.002
Molecular Therapy : the Journal of the American Society O... Samelson-Jones BJ
Jun 16th, 2022 - Worldwide use of factor IX Padua for hemophilia B gene therapy.|2022|Samelson-Jones BJ,|
https://clinicaltrials.gov/ct2/show/NCT05421429
Jun 16th, 2022 - This study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of multiple subcutaneous doses of KN057 in subjects with hemophilia A or B, with or without inhibitors to Factor VIII (FVIII) or Factor IX...
https://clinicaltrials.gov/ct2/show/NCT05145127
May 31st, 2022 - Study B7841007 is an open-label extension study to assess the long-term safety, tolerability, and efficacy of prophylaxis treatment with marstacimab in participants who did not require "Early Termination" from the Phase 3 Study B7841005. Approxima...
Drugs 24 results see all →
Clinicaltrials.gov 83 results
https://clinicaltrials.gov/ct2/show/NCT03358836
Jun 22nd, 2022 - This is a prospective, non-randomized, controlled study to examine whether or not having a higher trough during prophylactic treatment with clotting factor offers better joint protection than the standard trough of 1% Factor IX (FIX or Factor 9). ...
https://clinicaltrials.gov/ct2/show/NCT05421429
Jun 16th, 2022 - This study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of multiple subcutaneous doses of KN057 in subjects with hemophilia A or B, with or without inhibitors to Factor VIII (FVIII) or Factor IX...
https://clinicaltrials.gov/ct2/show/NCT05145127
May 31st, 2022 - Study B7841007 is an open-label extension study to assess the long-term safety, tolerability, and efficacy of prophylaxis treatment with marstacimab in participants who did not require "Early Termination" from the Phase 3 Study B7841005. Approxima...
https://clinicaltrials.gov/ct2/show/NCT03307980
May 26th, 2022 - Evaluation of the long-term level of persistence and potential late or delayed adverse events associated with PF-06838435 (formerly SPK-9001), assessment of the durability of the transgene expression, and determination of the effects of PF-0683843...
https://clinicaltrials.gov/ct2/show/NCT05044845
May 26th, 2022 - This prospective cohort study will use qualitative methods, specifically semi structured interviews to evaluate knowledge, beliefs, and attitude about gene therapy in patients 12 years and older with a diagnosis of moderate and severe hemophilia B...
News 166 results
https://www.medscape.com/viewarticle/968936
Feb 22nd, 2022 - Nearly all patients treated with a one-time gene therapy shot for hemophilia B (HB) were able to discontinue full-dose bleeding prophylaxis, a new industry-funded phase 3 study finds, and annual bleed rates (ABR) fell by 64% after the lead-in peri...
https://www.mdedge.com/hematology-oncology/article/251916/bleeding-disorders/gene-therapy-one-and-done-hemophilia-b
Randy Dotinga
Feb 17th, 2022 - Nearly all patients treated with a one-time gene therapy shot for hemophilia B (HB) were able to discontinue full-dose bleeding prophylaxis, a new industry-funded phase 3 study finds, and annual bleed rates (ABR) fell by 64% after the lead-in peri.
https://www.mdedge.com/hematology-oncology/article/243887/bleeding-disorders/recombinant-factor-ix-fusion-protein-benefited
Mark S. Lesney, PhD
Aug 4th, 2021 - Recombinant factor IX Fc fusion protein was effective, both as prophylaxis and in the treatment of bleeding episodes in previously untreated boys (< 18 years of age) with hemophilia B, according to Beatrice Nolan, MD, of Children’s Health Ireland.
https://www.medscape.com/viewarticle/951014
May 12th, 2021 - As the burden of hemophilia B in patients increases from mild to severe forms of the disease, the already high economic cost of treatment rises significantly, according to a large retrospective database study. Researchers developed four profile ca...
https://www.mdedge.com/hematology-oncology/article/239902/bleeding-disorders/health-costs-over-25-times-higher-hemophilia-b
Mark S. Lesney, PhD
May 11th, 2021 - As the burden of hemophilia B in patients increases from mild to severe forms of the disease, the already high economic cost of treatment rises significantly, according to a large retrospective database study. Researchers developed four profile ca.